Loading...
Market
Story
FDA Approves Eli Lilly's EBGLYSS™ Eczema Drug for Adults and Children on Friday
Sep 13, 2024, 11:10 PM
Eli Lilly announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its eczema drug, EBGLYSS™ (lebrikizumab-lbkz), for use in adults and children aged 12 years and older. The drug is intended to treat moderate-to-severe atopic dermatitis, a condition characterized by itchy, dry, and scaly skin. This approval marks a significant advancement for individuals suffering from eczema, offering a new treatment option for a diverse group of patients.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Asia-Pacific • 25%
North America • 25%
Europe • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
China • 25%
Europe • 25%
Middle East • 25%
Other • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
China • 25%
United States • 25%
Europe • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%